2022
Biomarkers of ketamine's antidepressant effect: An umbrella review
Meshkat S, Ho R, Cao B, Teopiz K, Rosenblat J, Rhee T, Di Vincenzo J, Ceban F, Jawad M, McIntyre R. Biomarkers of ketamine's antidepressant effect: An umbrella review. Journal Of Affective Disorders 2022, 323: 598-606. PMID: 36521662, DOI: 10.1016/j.jad.2022.12.021.Peer-Reviewed Original ResearchConceptsKetamine's antidepressant effectsAntidepressant effectsUmbrella reviewMajor depressive disorder (MDD) pathogenesisRapid acting antidepressant (RAAD) effectsMechanistically relevant biomarkersPotential peripheral biomarkerTreatment-resistant patientsAnti-inflammatory effectsNMDA receptor antagonistReal-world populationTreatment response predictionInflammatory markersPeripheral biomarkersKetamine actionReceptor antagonistSymptom deteriorationClinical utilityNeuroimaging biomarkersDisorder pathogenesisSynaptic plasticityCingulate cortexSystematic reviewKetamineFunctional connectivity
2019
N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects
Fogaça MV, Fukumoto K, Franklin T, Liu RJ, Duman CH, Vitolo OV, Duman RS. N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects. Neuropsychopharmacology 2019, 44: 2230-2238. PMID: 31454827, PMCID: PMC6898593, DOI: 10.1038/s41386-019-0501-x.Peer-Reviewed Original ResearchConceptsNovelty-suppressed feeding testMedial prefrontal cortexD-methadoneNMDA receptor antagonistAntidepressant actionPhospho-p70S6 kinaseReceptor antagonistN-methyl-D-aspartate receptorsNoncompetitive NMDA receptor antagonistTreatment-resistant patientsChronic unpredictable stressRapid antidepressant actionsDissociative side effectsPrimary cortical culturesMeasures of anhedoniaKetamine inducesAvailable antidepressantsTolerability profileAntidepressant effectsBDNF releaseAntidepressant responseResistant patientsFavorable safetySingle doseCortical culturesThe effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography
Baldinger-Melich P, Gryglewski G, Philippe C, James GM, Vraka C, Silberbauer L, Balber T, Vanicek T, Pichler V, Unterholzner J, Kranz GS, Hahn A, Winkler D, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Frey R, Lanzenberger R. The effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography. Brain Stimulation 2019, 12: 714-723. PMID: 30635228, DOI: 10.1016/j.brs.2018.12.976.Peer-Reviewed Original ResearchConceptsElectroconvulsive therapyTRD patientsMAO-A levelsHealthy subjectsPositron emission tomographyTest-retest variabilityMechanism of actionEffective antidepressant treatment strategiesSex-matched healthy subjectsEmission tomographyAntidepressant treatment strategiesMonoamine oxidaseTreatment-resistant depressionTreatment-resistant patientsSerotonin 1A receptorUnmedicated depressed patientsCerebral monoamine oxidasesCerebral MAOAntidepressant pharmacotherapyECT sessionsAntidepressant treatmentDepressed patientsMajor depressionSerotonergic systemTreatment strategies
2014
Expression of the 5-HT1A Serotonin Receptor in the Hippocampus Is Required for Social Stress Resilience and the Antidepressant-Like Effects Induced by the Nicotinic Partial Agonist Cytisine
Mineur YS, Einstein EB, Bentham MP, Wigestrand MB, Blakeman S, Newbold SA, Picciotto MR. Expression of the 5-HT1A Serotonin Receptor in the Hippocampus Is Required for Social Stress Resilience and the Antidepressant-Like Effects Induced by the Nicotinic Partial Agonist Cytisine. Neuropsychopharmacology 2014, 40: 938-946. PMID: 25288485, PMCID: PMC4330507, DOI: 10.1038/npp.2014.269.Peer-Reviewed Original ResearchMeSH Keywords8-Hydroxy-2-(di-n-propylamino)tetralinAlkaloidsAnimalsAntidepressive AgentsAzocinesDisease Models, AnimalDrug SynergismFluoxetineGene Expression RegulationHEK293 CellsHindlimb SuspensionHippocampusHumansInterpersonal RelationsMaleMiceMice, Inbred C57BLMotor ActivityQuinolizinesReceptor, Serotonin, 5-HT1ASelective Serotonin Reuptake InhibitorsSerotonin Receptor AgonistsStress, PsychologicalConceptsAntidepressant-like effectsSelective serotonin reuptake inhibitorsDorsal rapheCholinergic systemAgonist cytisineNicotinic acetylcholine receptor blockersEffects of cytisineTreatment-resistant patientsSerotonin reuptake inhibitorsAcetylcholine receptor blockerSSRI fluoxetineReceptor blockersAntidepressant efficacyReuptake inhibitorsSerotonin depletionCholinergic drugsMood disordersSerotonin receptorsMouse modelPharmacological approachesHippocampusReceptorsCytisineRapheMolecular mechanisms
2004
Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial.
Perry EB, Berman RM, Sanacora G, Anand A, Lynch-Colonese K, Charney DS. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. The Journal Of Clinical Psychiatry 2004, 65: 238-43. PMID: 15003079, DOI: 10.4088/jcp.v65n0215.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAdultAgedConnecticutCross-Over StudiesDepressive Disorder, MajorDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationFemaleFluoxetineHospitals, VeteransHumansMaleMiddle AgedParoxetinePersonality InventoryPindololSelective Serotonin Reuptake InhibitorsSertralineTreatment OutcomeVeteransConceptsSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitorsPindolol augmentationMajor depressive disorderControl groupReuptake inhibitorsDepressed patientsDepressive disorderTreatment-resistant depressed patientsDSM-IV major depressive disorderEfficacy of pindololPartial response rateTreatment-resistant patientsPrimary outcome measureHAM-D scoresHamilton Rating ScaleSSRI monotherapyAdequate trialClinical responseAntidepressant responseSSRI administrationWeek 4Outcome measuresWeek 6Insufficient responseCombining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study
Nelson JC, Mazure CM, Jatlow PI, Bowers MB, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biological Psychiatry 2004, 55: 296-300. PMID: 14744472, DOI: 10.1016/j.biopsych.2003.08.007.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic Uptake InhibitorsAdultAntidepressive Agents, Second-GenerationAntidepressive Agents, TricyclicChromatography, High Pressure LiquidDepressive DisorderDesipramineDouble-Blind MethodDrug Therapy, CombinationFemaleFluoxetineHumansMaleMiddle AgedNorepinephrinePsychiatric Status Rating ScalesSelective Serotonin Reuptake InhibitorsSerotoninTreatment OutcomeConceptsMontgomery-Asberg Depression Rating ScaleHamilton Depression Rating Scale scoresDepression Rating Scale scoresNonpsychotic unipolar major depressionPatient withdrew consentTreatment-resistant patientsWeeks of hospitalizationWeeks of treatmentCombination of fluoxetineOnset of actionAdequate plasma levelsDouble-blind conditionsDepression Rating ScaleTreatment of depressionRating Scale scoresUnipolar major depressionDrug plasma concentrationsDMI doseWithdrew consentAntidepressant medicationRandomized studyReuptake inhibitionSerotonergic agentsPlasma levelsMajor depression
2000
A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression
Berman R, Narasimhan M, Sanacora G, Miano A, Hoffman R, Hu X, Charney D, Boutros N. A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biological Psychiatry 2000, 47: 332-337. PMID: 10686268, DOI: 10.1016/s0006-3223(99)00243-7.Peer-Reviewed Original ResearchConceptsRepetitive transcranial magnetic stimulationTranscranial magnetic stimulationMajor depressionHDRS scoresMagnetic stimulationEfficacy of rTMSHamilton Depression Rating Scale scoresActive repetitive transcranial magnetic stimulationRandomized double-blind mannerTreatment-resistant major depressionDepression Rating Scale scoresDouble-blind mannerTreatment-resistant patientsRandomized clinical trialsRating Scale scoresMotor threshold determinationActive treatmentSham treatmentTreatment trialsClinical trialsTreatment resistanceMean decreaseDepressive symptomsControl groupScale score
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply